Reference (Dec-20-A3)
References
1. Mohanan Geetha Gopisankar. (2017). CYP2D6 pharmacogenomics, Egyptian Journal of Medical Human Genetics, Volume 18, Issue 4, Pages
309-313, ISSN 1110-8630, https://doi.org/10.1016/j.ejmhg.2017.03.001.
2. U.S. Food and Drug Administration/Center for Drug Evaluation and Research. (2020). Table of pharmacogenetic associations.
3. U.S. Food and Drug Administration/Center for Drug Evaluation and Research. (2018). Preventable Adverse Drug Reactions: A Focus on Drug
Interactions.
4. Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T., & Leeder, J. S. (2017). Prediction of CYP2D6 phenotype from genotype across world
populations. Genetics in medicine : official journal of the American College of Medical Genetics, 19(1), 69–76. https://doi.org/10.1038/gim.2016.80
5. Bradford, L., 2004. (n.d.). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Retrieved November 19,
2020, from https://doi.org/10.1517/14622416.3.2.229
6. Dean L. Aripiprazole Therapy and CYP2D6 Genotype. 2016 Sep 22. In: Pratt VM, McLeod HL, Rubinstein WS, et al., editors. Medical Genetics
Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK385288/
7. Dean L. Codeine Therapy and CYP2D6 Genotype. 2012 Sep 20 [Updated 2017 Mar 16]. In: Pratt VM, McLeod HL, Rubinstein WS, et al., editors.
Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK100662/
8. Cui, Y., Yan, H., Su, Y., Wang, L., Lu, T., Zhang, D., & Yue, W. (2020). CYP2D6Genotype-Based Dose Recommendations for Risperidone in
Asian People. Frontiers in pharmacology, 11, 936. https://doi.org/10.3389/fphar.2020.00936
9. Adams, J. (2008) Pharmacogenomics and personalized medicine. Nature Education 1(1):194.
https://www.nature.com/scitable/topicpage/pharmacogenomics-and-personalized-medicine-643/
